HealthLynked Corp. Strengthens Leadership with Appointment of Andrew Mavliev as Chief Technology and Product Officer
Summary
Full Article
HealthLynked Corp. (OTCQB: HLYK), a pioneer in connected healthcare technology, has announced the appointment of Andrew Mavliev as its new Chief Technology and Product Officer. This strategic move underscores the company's commitment to revolutionizing healthcare through technology. Mavliev brings over 15 years of expertise in technology strategy and product development, notably as the founding CTO of Aram Meem LLC's ToYou superapp. His leadership is expected to propel HealthLynked's initiatives in expanding its AI-powered healthcare platform, enhancing telehealth services, and integrating medical record systems more effectively.
Dr. Michael Dent, CEO of HealthLynked, expressed confidence in Mavliev's ability to drive the company's mission forward. Mavliev's proven track record in scaling secure, compliant direct-to-consumer platforms aligns with HealthLynked's vision for more accessible and personalized healthcare solutions. This appointment signals a significant step in the company's efforts to leverage technology for improving patient-provider interactions and healthcare outcomes globally.
HealthLynked Corp. is at the forefront of transforming healthcare by enabling the efficient exchange of medical information between patients and providers. The company's innovative network offers members a centralized and secure platform to manage their healthcare actively. With Mavliev at the helm of technology and product development, HealthLynked is poised to enhance its offerings and impact on the healthcare industry significantly.
For further details on HealthLynked Corp. and its initiatives, interested parties can visit https://www.healthlynked.com. Investors looking for the latest updates on HLYK can find comprehensive information in the company's newsroom at https://ibn.fm/HLYK.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 92799